PRIMARY INFORMATION |
---|
ID | 1224 |
PMID | 12695068 |
Year | 2003 |
Sequence | (Chain A: GIVEQCCTSICSLYQLENYCN) (Chain B: FVNQHLCGSHLVEALYLVCGERGFFYTPKT) |
Name | Insulin in poloxamer gel 407 |
Length | 51 |
N-Terminal Modification | Free |
C-Terminal Modification | Free |
Linear/ Cyclic | Cyclic (Chain A: C6-C11)(Chain A:C7-Chain B:C7) (Chain A:C20-Chain B:C19) |
Chirality | L |
Chemical Modification | None |
Origin of Peptide | Polypeptide |
Nature of Peptide/Cargo | It is used in the treatment diabetes mellitus and has immense therapeutic and commercial importance |
Mechanism | Not mentioned |
Cargo Sequence/Structure | None |
Name of cargo
| Not applicable |
Assay | Franz diffusion cells, Radioimuunoassay |
Enhancer | Menthone |
Properties of enhancer | Not mentioned |
Concentration | 500 µl of gel formulation with 500 µl of menthone (5% v / v) |
Incubation time | 2 h |
Tissue permeability (value with units) | Skin permeation parameters of insulin from poloxamer 407 gel using menthone enhancer, Lag time (h)=1.20 (0.02) , Flux (µg/cm2 /h)=5.57 (0.13), Cumulative amount permeated (µg)=210.78 (2.64), Skin affinity=10.57 (0.38), (P<0.05), all values are n=3 |
Tissue Sample | Female Sprague–Dawley rat skin |
Ex vivo/In vivo/In vitro | ex vivo |
SECONDARY INFORMATION |
---|
STRUCTURE | |
SMILES | N.A. |